Pliant Therapeutics reports positive Phase 2a data for PLN-74809 in IPF; FVC and QLF improved

PLIANT THERAPEUTICS, INC.

INTEGRIS-IPF Phase 2a met primary and secondary endpoints; PLN-74809 well tolerated with no drug-related SAEs or discontinuations.
Pooled PLN-74809 showed 80% reduction in FVC decline vs placebo (-15.1 mL vs -74.1 mL); 80 mg dose showed +24.6 mL FVC increase from baseline.
Dose-dependent reduction in ≥10% FVCpp decline: 18.2% (40mg), 8.7% (80mg), 4.5% (160mg) vs 17.4% placebo.
QLF imaging showed dose-dependent antifibrotic effect; 160 mg group showed 0.00% mean change vs 1.15% placebo.
Company to discuss data with regulators; 320 mg cohort data expected early 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.